Madrigal Pharmaceuticals : MDGL F4c Webcast Presentation 2025 v25

Published: 2025-05-13 08:07:10 ET MDGL

Published on 05/13/2025 at 08:07

May 13, 2025

© 2025 Madrigal Pharmaceuticals, Inc. All rights reserved.

Madrigal: Extending Our Leadership in MASH

Bill Sibold

Chief Executive Officer Madrigal

Overview of Compensated MASH Cirrhosis (F4c) and Clinically Significant Portal Hypertension

Michael Charlton, M.B.B.S. Senior Vice President, Clinical Development Madrigal

EASL 2025: Rezdiffra Open-Label Compensated MASH Cirrhosis (F4c) Arm of the Phase 3 MAESTRO-NAFLD-1 Trial

Naim Alkouri, M.D.

Chief Academic Officer, Summit Clinical Research; Director of the Steatotic Liver Disease Program, Clinical Research Institute of Ohio

Q&A Bill Sibold, Michael Charlton and Naim Alkouri

3

4

cause of liver transplants for women

cause of liver transplants for men

5

Disclaimer

Madrigal Pharmaceuticals Inc. published this content on May 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2025 at 12:06 UTC.